Nitrous Oxide: an emerging novel treatment for treatment-resistant depression.

Autor: Quach DF; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, United States of America., de Leon VC; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, United States of America., Conway CR; Department of Psychiatry, Washington University School of Medicine, Saint Louis, MO, United States of America. Electronic address: conwaycr@wustl.edu.
Jazyk: angličtina
Zdroj: Journal of the neurological sciences [J Neurol Sci] 2022 Mar 15; Vol. 434, pp. 120092. Date of Electronic Publication: 2021 Dec 16.
DOI: 10.1016/j.jns.2021.120092
Abstrakt: Stemming from the results of the historic STAR-D trial, it is evident that a significant subset of individuals (20-25%) with major depressive disorder (MDD) do not respond to conventional antidepressant medications. As a result, an emphasis has been placed on the development of novel therapeutics for MDD over the last two decades. Recently, substantial research efforts have been focused on the use of ketamine as an antidepressant whose mechanism of action is via the N-methyl-d-aspartate (NMDA) receptor. Another potential therapeutic compound of interest is nitrous oxide, which has been utilized for more than a century in multiple fields of medicine for its analgesic and anesthetic properties. Recent clinical studies suggest that nitrous oxide may be effective for treatment-resistant depression. In this review, we will discuss the administration of nitrous oxide as a psychiatric intervention, current use in psychiatry, putative mechanisms of action, and future directions highlighting knowledge gaps and other potential utilities in the field of psychiatry.
(Copyright © 2021 Elsevier B.V. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: